

Supporting Information

Asymmetric Tandem Reactions of *N*-Sulfonylimines and α,β -Unsaturated Aldehydes: An Alternative Reaction Pathway to That of Using Saturated Aldehydes

Qianjin An,^a Jing Li^a, Jiefeng Shen,^a Nicholas Butt,^a Delong Liu,^{a,*} Yangang Liu^a and Wanbin Zhang^{a,b,*}

^a School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, P. R. China

^b School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, P. R. China

Fax: (+)86-21-54743265; Phone: (+)86-21-54743265; e-mail: wanbin@sjtu.edu.cn


Contents

1. General Information.....	S2
2. Data for Substrates.....	S2
3. References.....	S3
4. General Procedure for the Organocatalytic Tandem Reactions	S4
5. Procedure for the Synthesis of 4 and 5	S17
6. X-ray Data of Compound 3f	S19
7. NMR Spectra	S21
8. HPLC Spectra	S52


1. General Information

^1H NMR (400 MHz) and ^{13}C NMR (100 MHz) spectra were recorded on a Varian MERCURY plus-400 spectrometer with TMS as an internal standard. HRMS was performed at the Analysis Center of Shanghai Jiao Tong University. Enantioselectivity was measured by high performance liquid chromatography (HPLC) using Daicel Chiralcel AS-H, OD-H and IC-3 columns with hexane / *i*-PrOH as a eluent. Column chromatography was performed using 100–200 mesh silica gel. Melting points were measured with SGW X-4 micro melting point apparatus. All commercially available substrates were used as received.


2. Data for Substrates^[1-6]



3-Methylbenzo[d]isothiazole 1,1-dioxide (1a): White solid (2.6 g, 68%). ^1H NMR (400 MHz, CDCl_3): δ 7.93 – 7.91 (m, 1H), 7.76 – 7.74 (m, 2H), 7.70 – 7.68 (m, 1H), 2.67 (s, 3H).




3,5-Dimethylbenzo[d]isothiazole 1,1-dioxide (1b): White solid (0.6 g, 65%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 8.00 (d, J = 7.6 Hz, 1H), 7.85 (s, 1H), 7.68 (d, J = 7.6 Hz, 1H), 2.66 (s, 3H), 2.47 (s, 3H).




5-(*tert*-Butyl)-3-methylbenzo[d]isothiazole 1,1-dioxide (1c): white solid (0.2 g, 60%), m.p. 186 – 187 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.83 (d, J = 8.0 Hz, 1H), 7.76 (dd, J = 8.0, 1.6 Hz, 1H), 7.63 (d, J = 1.2 Hz, 1H), 2.65 (s, 3H), 1.38 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3): δ 173.6, 158.8, 136.9, 132.2, 130.9, 122.3, 121.1, 35.8, 31.3, 17.6; IR: 2963, 2874, 1557, 1465, 1416, 1372, 1319,

1276, 1184, 1153, 1103, 1020, 892, 837, 797, 736, 625; HRMS (ESI): calcd for C₁₂H₁₆NO₂S [M+H]⁺: 238.0902, found 238.0903.



5-Methoxy-3-methylbenzo[d]isothiazole 1,1-dioxide (1d): white solid (0.4 g, 54%). m.p. 169 – 170 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.03 (d, *J* = 8.4 Hz, 1H), 7.53 (d, *J* = 2.4 Hz, 1H), 7.35 (dd, *J* = 8.4, 2.4 Hz, 1H), 3.91 (s, 3H), 2.66 (s, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆): δ 175.1, 164.7, 134.4, 130.5, 124.1, 119.6, 111.6, 57.1, 18.1; IR: 1614, 1556, 1316, 1275, 1239, 1170, 1123, 1069, 836, 801, 730, 607, 554; HRMS (ESI): calcd for C₉H₁₀NO₃S [M-H]⁻: 211.9993, found 211.9989.




3-Methyl-5-(trifluoromethyl)benzo[d]isothiazole 1,1-dioxide (1e): white solid (0.3 g, 54%). m.p. 210 – 212 °C; ¹H NMR (400 MHz, CDCl₃): δ 8.06 – 8.02 (m, 2H), 7.91 (s, 1H), 2.73 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 172.0, 142.8, 132.5, 130.9, 123.2, 121.4, 17.9; IR: 1614, 1556, 1316, 1275, 1239, 1170, 1123, 1069, 836, 801, 730, 607, 554; HRMS (ESI): calcd for C₉H₇F₃NO₂S [M+H]⁺: 250.0150, found 250.0147.


3. References

- [1] J. G. Lombardino, *J. Org. Chem.* 1971, **36**, 1843.
- [2] F. A. Davis, J. C. Towson, D. B. Vashi, R. Thimmareddy, J. P. Mccauley, M. E. Harakal, Jr. and D. J. Gosciniaik, *J. Org. Chem.* 1990, **55**, 1254.
- [3] L. Xu, H. Shu, Y. Liu, S. H. Zhang and M. L. Trudell, *Tetrahedron* 2006, **62**, 7902.
- [4] Q. Yang, G. Shang, W. Z. Gao, J. G. Deng and X. M. Zhang, *Angew. Chem., Int. Ed.* 2006, **45**, 3832.
- [5] X. F. Xiong, H. Zhang, J. Peng and Y.-C. Chen, *Chem. Eur. J.* 2011, **17**, 2358.
- [6] G. Yang and W. Zhang, *Angew. Chem., Int. Ed.* 2013, **52**, 7540.


4. General Procedure for the Organocatalytic Tandem Reactions




The **cat** (4.3 mg, 0.01 mmol), DMAP (12.2 mg, 0.10 mmol) and different α,β -unsaturated aldehydes (1.2 equiv, 0.12 mmol) were dissolved in DCM (1 mL) at 25 °C. The solution was stirred for 5 min, and then the appropriate cyclic sulfamidate (0.10 mmol) was added. The reaction mixture was stirred at 25 °C until the complete consumption of cyclic sulfamidate (monitored by TLC). The solvent was then evaporated and the crude products was purified by flash column silica-gel chromatography (PE / EA = 6 / 1) to give the adduct **3**. Remarkably, the direct organocatalytic tandem reaction can be easily scaled up to a gram-scale. Thus, treating **1a** (1.00 g) with (*E*)-3-(2-chlorophenyl)acrylaldehyde **2f** (0.92 g, 1.2 equiv) under the standard reaction conditions smoothly provided the desired product **3f** (1.33 g, 70%, > 20:1 dr and 98% ee).




(7*R*,9*R*)-9-Methyl-7-hydroxy-8,9-dihydro-7*H*-benzo[4,5]isothiazolo[2,3-*a*]pyridine 5,5-dioxide (3a): Colorless oil (22.6 mg, 90%). ¹H NMR (400 MHz, CDCl₃): δ 7.78 (d, *J* = 7.6 Hz, 1H), 7.67 – 7.60 (m, 2H), 7.55 – 7.51 (m, 1H), 5.86 (t, *J* = 2.8 Hz, 1H), 5.62 (dd, *J* = 2.4, 0.8 Hz, 1H), 3.54 (s, 1H), 2.90 – 2.80 (m, 1H), 2.26 – 2.20 (m, 1H), 1.58 – 1.51 (m, 1H), 1.20 (d, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 133.4, 132.0, 130.0, 128.2, 121.4, 121.2, 108.2, 72.3, 36.0, 23.4, 20.6; HRMS (ESI): calcd for C₁₂H₁₂NO₃S [M-H]⁺: 250.0538, found 250.0531; IR: 3456, 2960, 2928, 2872, 1732, 1665, 1469, 1384, 1335, 1301, 1252, 1176, 1161, 1029, 980, 950, 872, 760; HPLC (Chiralcel IC-3, Hexane / *i*-PrOH = 90 : 10, UV = 254 nm, flow rate = 1.0 mL / min) *t*_{R1} = 79.51 min (major) and *t*_{R2} = 110.88 min (minor); ee = 83%; [α]_D²⁵ = +38.6 (*c* 0.2, CH₃OH).




(7R,9R)-9-Ethyl-7-hydroxy-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridine 5,5-dioxide (3b): Pale yellow solid (24.4 mg, 92%). m.p. 100 – 101 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.79 (d, $J = 7.6$ Hz, 1H), 7.70 – 7.68 (m, 1H), 7.65 – 7.61 (m, 1H), 7.56 – 7.52 (m, 1H), 5.88 (t, $J = 2.8$ Hz, 1H), 5.70 – 5.69 (m, 1H), 3.49 (s, 1H), 2.70 – 2.64 (m, 1H), 2.30 – 2.23 (m, 1H), 1.61 – 1.52 (m, 1H), 1.04 (t, $J = 7.6$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 133.3, 132.0, 130.1, 130.0, 128.5, 121.4, 121.2, 106.6, 72.3, 33.7, 29.84, 27.9, 11.4; HRMS (ESI): calcd for $\text{C}_{13}\text{H}_{14}\text{NO}_3\text{S}$ [$\text{M}-\text{H}$] $^-$: 264.0694, found 264.0690; IR: 3480, 2963, 2924, 2852, 1732, 1716, 1668, 1470, 1338, 1304, 1260, 1177, 1134, 1023, 949, 800, 761, 592, 571, 523; HPLC (Chiralcel IC-3, Hexane / *i*-PrOH = 80 : 20, UV = 254 nm, flow rate = 0.9 mL / min) $t_{\text{R}1}$ = 44.87 min (major) and $t_{\text{R}2}$ = 58.81 min (minor); ee = 91%; $[\alpha]_D^{25} = +9.5$ (*c* 0.2, CH_3OH).




(7R,9R)-7-Hydroxy-9-propyl-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridine 5,5-dioxide (3c): Colorless oil (25.9 mg, 93%). ^1H NMR (400 MHz, CDCl_3): δ 7.79 (d, $J = 8.0$ Hz, 1H), 7.69 – 7.61 (m, 2H), 7.55 – 7.52 (m, 1H), 5.87 (s, 1H), 5.69 (d, $J = 1.2$ Hz, 1H), 3.54 (s, 1H), 2.77 – 2.74 (m, 1H), 2.28 – 2.22 (m, 1H), 1.57 – 1.44 (m, 5H), 0.98 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 133.3, 131.9, 130.1, 129.9, 128.3, 121.3, 121.2, 106.8, 72.2, 37.2, 34.2, 28.0, 20.1, 14.3; HRMS (ESI): calcd for $\text{C}_{14}\text{H}_{16}\text{NO}_3\text{S}$ [$\text{M}-\text{H}$] $^-$: 278.0851, found 278.0844; IR: 3449, 2958, 2928, 2872, 2026, 1638, 1455, 1384, 1338, 1301, 1176, 1051, 950, 753, 592, 533; HPLC (Chiralcel IC-3, Hexane / *i*-PrOH = 80 : 20, UV = 254 nm, flow rate = 0.9 mL / min) $t_{\text{R}1}$ = 44.80 min (major) and $t_{\text{R}2}$ = 57.90 min (minor); ee = 93%; $[\alpha]_D^{25} = +15.3$ (*c* 0.2, CH_3OH).



(7*R*,9*R*)-7-Hydroxy-9-*iso*-propyl-8,9-dihydro-7*H*-benzo[4,5]isothiazolo[2,3-*a*]pyridine 5,5-dioxide (3d): White solid (22.9 mg, 82%). m.p. 153 – 154 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.79 (d, *J* = 8.0 Hz, 1H), 7.71 (d, *J* = 8.0 Hz, 1H), 7.66 – 7.61 (m, 1H), 7.54 (t, *J* = 7.2 Hz, 1H), 5.91 (t, *J* = 2.8 Hz, 1H), 5.72 – 5.71 (m, 1H), 3.57 (s, 1H), 2.68 – 2.62 (m, 1H), 2.19 – 2.09 (m, 1H), 1.87 – 1.80 (m, 1H), 1.71 – 1.64 (m, 1H), 1.00 (dd, *J* = 6.4, 2.4 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 133.3, 130.2, 130.1, 130.0, 129.1, 121.4, 121.2, 105.4, 72.5, 34.4, 31.4, 30.6, 19.7, 19.7; HRMS (ESI): calcd for C₁₄H₁₆NO₃S [M+H]⁺: 280.1007, found 280.1008; IR: 2960, 2926, 2868, 1457, 1471, 1397, 1301, 1223, 1175, 1160, 1130, 1105, 1046, 1029, 1010, 990, 758, 600, 582; HPLC (Chiralcel IC-3, Hexane / *i*-PrOH = 80 : 20, UV = 254 nm, flow rate = 0.9 mL / min) t_{R1} = 44.42 min (major) and t_{R2} = 55.44 min (minor); ee = 98%; [α]_D²⁵ = +25.5 (*c* 0.1, CH₃OH).




(7*R*,9*R*)-7-Hydroxy-9-phenyl-8,9-dihydro-7*H*-benzo[4,5]isothiazolo[2,3-*a*]pyridine 5,5-dioxide (3e): White solid (26.4 mg, 84%). m.p. 131 – 133 °C ; ¹H NMR (400 MHz, CDCl₃): δ 7.84 (d, *J* = 7.6 Hz, 1H), 7.70 – 7.63 (m, 2H), 7.60 – 7.56 (m, 1H), 7.39 – 7.35 (m, 2H), 7.32 – 7.29 (m, 3H), 5.93 (dd, *J* = 5.2, 2.8 Hz, 1H), 5.83 (dd, *J* = 2.4, 1.2 Hz, 1H), 4.03 (ddd, *J* = 12.4, 6.0, 2.8 Hz, 1H), 3.70 (t, *J* = 2.4 Hz, 1H), 2.49 – 2.44 (m, 1H), 1.99 – 1.93 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 143.4, 133.3, 131.9, 130.1, 129.8, 128.9, 128.9, 127.7, 127.1, 121.3, 121.2, 105.6, 72.1, 36.8, 34.9; HRMS (ESI): calcd for C₁₇H₁₄NO₃S [M-H]⁻: 312.0694, found 312.0686; IR: 3454, 2927, 2026, 1638, 1470, 1453, 1384, 1304, 1264, 1174, 1159, 1063, 1047, 949, 891, 758, 701, 664, 594, 561, 527; HPLC (Chiralcel AS-H, Hexane / *i*-PrOH = 80 : 20, UV = 254 nm, flow rate = 0.7 mL / min), t_{R1} = 27.18 min (major) and t_{R2} = 47.40 min (minor); ee = 94%; [α]_D²⁵ = 7.4 (*c* 0.2, CH₃OH).




(7*R*,9*R*)-9-(2-Chlorophenyl)-7-hydroxy-8,9-dihydro-7*H*-benzo[4,5]isothiazolo[2,3-*a*]pyridine

5,5-dioxide (3f): White solid (29.6 mg, 85%). m.p. 165 – 166 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.84 – 7.82 (m, 1H), 7.73 – 7.64 (m, 2H), 7.60 – 7.56 (m, 1H), 7.42 – 7.39 (m, 1H), 7.31 – 7.18 (m, 3H), 5.92 (t, *J* = 2.8 Hz, 1H), 5.79 (dd, *J* = 2.4, 1.2 Hz, 1H), 4.54 (ddd, *J* = 12.0, 5.6, 2.8 Hz, 1H), 3.78 (s, 1H), 2.59 – 2.53 (m, 1H), 1.88 – 1.81 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 140.9, 133.9, 133.5, 132.1, 130.4, 130.0, 129.9, 129.8, 129.1, 128.5, 127.6, 121.5, 121.5, 104.7, 72.4, 34.8, 32.1; HRMS (ESI): calcd for C₁₇H₁₃NO₃SCl [M-H]⁻: 346.0305, found 346.0305; IR: 3470, 2927, 1649, 1471, 1438, 1384, 1305, 1261, 1175, 1159, 1102, 1063, 1051, 1034, 998, 949, 902, 822, 757, 715, 702, 654, 619, 597, 562, 537, 499; HPLC (Chiralcel AS-H, Hexane / *i*-PrOH = 80 : 20, UV = 254 nm, flow rate = 0.7 mL / min) t_{R1} = 28.38 min (major) and t_{R2} = 44.84 min (minor); ee = 95%; [α]_D²⁵ = +15.9 (*c* 0.2, CH₃OH).




(7*R*,9*R*)-9-(3-Chlorophenyl)-7-hydroxy-8,9-dihydro-7*H*-benzo[4,5]isothiazolo[2,3-*a*]pyridine

5,5-dioxide (3g): White solid (27.7 mg, 80%). m.p. 73 – 74 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.83 (d, *J* = 7.6 Hz, 1H), 7.72 – 7.65 (m, 2H), 7.61 – 7.57 (m, 1H), 7.29 – 7.26 (m, 3H), 7.19 – 7.17 (m, 1H), 5.92 (s, 1H), 5.78 – 5.76 (dd, *J* = 2.4, 1.2 Hz, 1H), 4.01 (ddd, *J* = 12.4, 5.6, 2.4 Hz, 1H), 3.72 (s, 1H), 2.47 – 2.41 (m, 1H), 1.92 (t, *J* = 12.0 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 145.7, 134.9, 133.6, 132.2, 130.5, 130.4, 130.1, 129.8, 129.5, 128.1, 127.5, 126.2, 121.5, 104.7, 72.2, 36.9, 35.0; HRMS (ESI): calcd for C₁₇H₁₄NO₃SCl [M+Na]⁺: 370.0281, found 370.0281; IR: 3453, 2920, 2850, 1640, 1596, 1470, 1430, 1384, 1305, 1259, 1175, 1159, 1095, 1062, 950, 917, 785, 759, 723, 694, 658, 598, 558; HPLC (Chiralcel AS-H, Hexane / *i*-PrOH = 70 : 30, UV = 254 nm, flow rate = 0.4 mL / min) t_{R1} = 31.97 min (major) and t_{R2} = 59.03 min (minor); ee = 98%; [α]_D²⁵ = +24.3 (*c* 0.3, CH₃OH).




(7R,9R)-9-(4-Chlorophenyl)-7-hydroxy-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridine 5,5-dioxide (3h): White solid (28.3 mg, 82%). m.p. 143 – 144 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.85 – 7.82 (m, 1H), 7.71 – 7.64 (m, 2H), 7.61 – 7.57 (m, 1H), 7.34 – 7.31 (m, 2H), 7.24 – 7.22 (m, 2H), 5.92 (t, *J* = 2.4 Hz, 1H), 5.76 (dd, *J* = 2.4, 1.2 Hz, 1H), 4.01 (ddd, *J* = 12.0, 5.6, 2.8 Hz, 1H), 3.69 (s, 1H), 2.46 – 2.40 (m, 1H), 1.94 – 1.87 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 142.1, 133.6, 133.0, 132.1, 130.5, 129.8, 129.4, 129.3, 129.2, 121.5, 121.5, 105.0, 72.2, 36.9, 34.6; HRMS (ESI): calcd for C₁₇H₁₃NO₃SCl [M-H]⁻: 346.0305, found 346.0293; IR: 3463, 1647, 1491, 1470, 1408, 1384, 1304, 1260, 1174, 1159, 1090, 1062, 1048, 1014, 950, 891, 831, 759, 625, 612, 596, 561, 522, 501; HPLC (Chiralcel AS-H, Hexane / *i*-PrOH = 70 : 30, UV = 254 nm, flow rate = 0.4 mL / min) *t*_{R1} = 37.06 min (major) and *t*_{R2} = 63.13 min (minor); ee > 99%; [α]_D²⁵ = +18.3 (*c* 0.2, CH₃OH).




(7R,9R)-9-(2-Fluorophenyl)-7-hydroxy-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridine 5,5-dioxide (3i): Pale yellow solid (29.8 mg, 90%). m.p. 171 – 172 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.83 (d, *J* = 7.6 Hz, 1H), 7.71 – 7.63 (m, 2H), 7.60 – 7.55 (m, 1H), 7.29 – 7.23 (m, 2H), 7.15 – 7.05 (m, 2H), 5.94 (dd, *J* = 5.2, 2.4 Hz, 1H), 5.78 (d, *J* = 1.6 Hz, 1H), 4.37 (ddd, *J* = 12.4, 5.6, 2.4 Hz, 1H), 3.70 (t, *J* = 2.4 Hz, 1H), 2.52 – 2.46 (m, 1H), 2.01 – 1.94 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 162.2, 159.8, 133.5, 132.1, 130.4, 130.1, 129.9, 129.5, 129.3, 129.3, 128.9, 128.8, 124.7, 124.7, 121.5, 121.4, 116.0, 115.8, 104.6, 72.3, 34.9, 28.6; HRMS (ESI): calcd for C₁₇H₁₃NO₃SF [M-H]⁻: 330.0600, found 330.0583; IR: 3468, 2925, 1666, 1584, 1491, 1470, 1455, 1384, 1305, 1262, 1226, 1174, 1160, 1109, 1062, 950, 908, 832, 792, 757, 658, 619, 597, 563; HPLC (Chiralcel AS-H, Hexane / *i*-PrOH = 90 : 10, UV = 254 nm, flow rate = 0.7 mL / min) *t*_{R1} =

57.11 min (major) and t_{R2} = 89.74 min (minor); ee = 99.7%; $[\alpha]^{25}_D$ = +39.9 (c 0.2, CH₃OH).




((7*R*,9*R*)-9-(3-Fluorophenyl)-7-hydroxy-8,9-dihydro-7*H*-benzo[4,5]isothiazolo[2,3-*a*]pyridine 5,5-dioxide (3j): Pale yellow solid (28.1 mg, 85%). m.p. 72 – 73 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.85 – 7.83 (m, 1H), 7.72 – 7.65 (m, 2H), 7.61 – 7.57 (m, 1H), 7.35 – 7.30 (m, 1H), 7.08 (d, J = 7.6 Hz, 1H), 7.02 – 6.96 (m, 2H), 5.93 (dd, J = 5.2, 2.4 Hz, 1H), 5.78 (dd, J = 2.4, 1.2 Hz, 1H), 4.03 (ddd, J = 12.4, 6.0, 2.8 Hz, 1H), 3.68 (t, J = 2.4 Hz, 1H), 2.48 – 2.42 (m, 1H), 1.96 – 1.89 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 164.3, 161.8, 146.0, 146.0, 133.4, 132.0, 130.4, 130.3, 129.6, 129.2, 123.4, 121.3, 114.7, 114.5, 114.1, 113.9, 104.6, 72.0, 36.6, 34.7; HRMS (ESI): calcd for C₁₇H₁₃NO₃SF [M-H]⁻: 330.0600, found 330.0578; IR: 3459, 2928, 2360, 1638, 1470, 1448, 1384, 1305, 1247, 1175, 1160, 1063, 948, 870, 760, 695, 585, 559; HPLC (Chiralcel AS-H, Hexane / *i*-PrOH = 70 : 30, UV = 254 nm, flow rate = 0.4 mL / min) t_{R1} = 30.40 min (major) and t_{R2} = 56.80 min (minor); ee = 99.5%; $[\alpha]^{25}_D$ = -26.0 (c 0.2, CH₃OH).




(7*R*,9*R*)-9-(4-Fluorophenyl)-7-hydroxy-8,9-dihydro-7*H*-benzo[4,5]isothiazolo[2,3-*a*]pyridine 5,5-dioxide (3k): White solid (28.9 mg, 87%). m.p. 161 – 162 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.85 – 7.82 (m, 1H), 7.71 – 7.64 (m, 2H), 7.61 – 7.57 (m, 1H), 7.27 – 7.23 (m, 2H), 7.07 – 7.00 (m, 2H), 5.92 (dd, J = 4.8, 2.4 Hz, 1H), 5.77 (dd, J = 2.4, 1.2 Hz, 1H), 4.02 (ddd, J = 12.0, 5.6, 2.4 Hz, 1H), 3.68 (t, J = 2.4 Hz, 1H), 2.46 – 2.40 (m, 1H), 1.95 – 1.87 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 163.3, 160.8, 139.3, 133.5, 132.2, 130.4, 129.9, 129.4, 129.3, 121.5, 121.5, 116.0, 115.8, 105.4, 72.3, 37.1, 34.5; HRMS (ESI): calcd for C₁₇H₁₃NO₃SF [M-H]⁻: 330.0600, found 330.0594; IR: 3455, 2928, 2342, 1664, 1604, 1509, 1470, 1384, 1304, 1261, 1222, 1174, 1158, 1107, 1063,

1049, 950, 893, 835, 787, 760, 639, 617, 596, 557, 532, 510; HPLC (Chiralcel AS-H, Hexane / *i*-PrOH = 70 : 30, UV = 254 nm, flow rate = 0.4 mL / min) t_{R1} = 32.65 min (major) and t_{R2} = 61.13 min (minor); ee = 99%; $[\alpha]^{25}_D$ = +13.9 (*c* 0.2, CH₃OH).




(7*R*,9*R*)-9-(4-Bromophenyl)-7-hydroxy-8,9-dihydro-7*H*-benzo[4,5]isothiazolo[2,3-*a*]pyridine 5,5-dioxide (3l): Pale yellow solid (30.5 mg, 78%). m.p. 174 – 176 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.85 – 7.83 (m, 1H), 7.71 – 7.65 (m, 2H), 7.61 – 7.57 (m, 1H), 7.50 – 7.48 (m, 2H), 7.19 – 7.16 (m, 2H), 5.92 (d, *J* = 2.0 Hz, 1H), 5.76 (dd, *J* = 2.4, 1.2 Hz, 1H), 4.00 (ddd, *J* = 12.4, 6.0, 2.8 Hz, 1H), 3.60 (t, *J* = 2.0 Hz, 1H), 2.46 – 2.40 (m, 1H), 1.94 – 1.86 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 142.4, 133.4, 132.0, 131.6, 130.3, 129.6, 129.4, 129.3, 104.7, 72.0, 36.6, 34.5; HRMS (ESI): calcd for C₁₇H₁₃NO₃SBr [M-H]⁻: 389.9800, found 389.9775; IR: 3461, 2926, 2853, 1647, 1487, 1470, 1404, 1384, 1304, 1244, 1174, 1159, 1063, 1049, 1009, 950, 892, 824, 759, 720, 684, 608, 595, 561, 534, 499; HPLC: (Chiralcel AS-H, Hexane / *i*-PrOH = 70 : 30, UV = 254 nm, flow rate = 0.4 mL / min) t_{R1} = 40.48 min (major) and t_{R2} = 68.16 min (minor); ee = 99%; $[\alpha]^{25}_D$ = +36.3 (*c* 0.3, CH₃OH).




(7*R*,9*R*)-7-Hydroxy-9-(4-(trifluoromethyl)phenyl)-8,9-dihydro-7*H*-benzo[4,5]isothiazolo[2,3-*a*]pyridine 5,5-dioxide (3m): Colorless oil (38.1 mg, 88%). ¹H NMR (400 MHz, CDCl₃): δ 7.84 (d, *J* = 7.6 Hz, 1H), 7.72 – 7.65 (m, 2H), 7.63 – 7.58 (m, 2H), 7.42 (d, *J* = 8.0 Hz, 2H), 5.94 (dd, *J* = 4.8, 2.4 Hz, 1H), 5.77 (dd, *J* = 2.4, 1.2 Hz, 1H), 4.10 (ddd, *J* = 12.4, 5.6, 2.4 Hz, 1H), 3.70 (d, *J* = 2.0 Hz, 1H), 2.49 – 2.43 (m, 1H), 1.97 – 1.90 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 147.5, 133.4, 132.0, 130.4, 129.6, 129.5, 129.5, 129.3, 128.4, 128.1, 125.8, 122.7, 121.4, 121.3, 104.1,

71.9, 36.6, 34.9; HRMS (ESI): calcd for $C_{18}H_{13}NO_3SF_3$ $[M-H]^-$: 380.0568, found 380.0560; IR: 3458, 2929, 2026, 1634, 1470, 1419, 1384, 1325, 1264, 1174, 1160, 1119, 1065, 1017, 949, 894, 759, 610, 560; HPLC: (Chiralcel AS-H, Hexane / *i*-PrOH = 70 : 30, UV = 254 nm, flow rate = 0.4 mL / min) t_{R1} = 26.38 min (major) and t_{R2} = 42.50 min (minor); ee = 96%; $[\alpha]^{25}_D$ = +25.0 (*c* 0.2, CH₃OH).



(7*R*,9*R*)-7-Hydroxy-9-(4-methoxyphenyl)-8,9-dihydro-7*H*-benzo[4,5]isothiazolo[2,3-


***a*]pyridine 5,5-dioxide (3n):** Colorless oil (25.1 mg, 73%). ¹H NMR (400 MHz, CDCl₃): δ 7.83 (d, *J* = 8.0 Hz, 1H), 7.70 – 7.63 (m, 2H), 7.59 – 7.55 (m, 1H), 7.22 – 7.19 (m, 2H), 6.90 – 6.88 (m, 2H), 5.92 (s, 1H), 5.80 (t, *J* = 1.2 Hz, 1H), 3.98 (ddd, *J* = 12.4, 6.0, 2.4 Hz, 1H), 3.81 (s, 3H), 3.68 (s, 1H), 2.45 – 2.39 (m, 1H), 1.92 (t, *J* = 12.0 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 158.8, 135.6, 133.5, 132.1, 130.3, 130.0, 129.0, 128.9, 121.5, 121.4, 114.4, 106.2, 72.4, 55.5, 37.1, 34.3; HRMS (ESI): calcd for $C_{18}H_{16}NO_4S$ $[M-H]^-$: 342.0800, found 342.0797; IR: 3452, 2928, 1637, 1512, 1469, 1384, 1304, 1250, 1174, 1159, 1063, 950, 830, 761, 538; HPLC (Chiralcel AS-H, Hexane / *i*-PrOH = 80 : 20, UV = 254 nm, flow rate = 0.7 mL / min) t_{R1} = 46.42 min (major); ee > 99%; $[\alpha]^{25}_D$ = +14.7 (*c* 0.3, CH₃OH).




(7*R*,9*R*)-7-Hydroxy-9-(2-methoxyphenyl)-8,9-dihydro-7*H*-benzo[4,5]isothiazolo[2,3-

***a*]pyridine 5,5-dioxide (3o):** White solid (27.4 mg, 80%). m.p. 83 – 85 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.84 – 7.81 (m, 1H), 7.71 – 7.69 (m, 1H), 7.65 (td, *J* = 7.2, 1.2 Hz, 1H), 7.56 (td, *J* = 8.0, 0.8 Hz, 1H), 7.29 – 7.21 (m, 2H), 7.21 (dd, *J* = 7.6, 1.6 Hz, 1H), 6.97 – 6.90 (m, 2H), 5.92 (dd, *J* = 4.8, 2.4 Hz, 1H), 5.82 (dd, *J* = 2.4, 1.2 Hz, 1H), 4.46 (ddd, *J* = 12.0, 5.6, 2.4 Hz, 1H), 3.86 (s, 3H), 3.60 (t, *J* = 2.4 Hz, 1H), 2.53 – 2.47 (m, 1H), 1.94 – 1.87 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ

157.0, 133.2, 131.8, 131.3, 130.0, 129.9, 128.9, 128.2, 128.0, 121.2, 121.2, 120.8, 110.5, 106.2, 72.5, 55.4, 34.4, 28.3; HRMS (ESI): calcd for C₁₈H₁₆NO₄S [M-H]⁻: 342.0800, found 342.0790; IR: 3457, 2928, 2026, 1640, 1492, 1469, 1384, 1303, 1242, 1174, 1159, 1047, 949, 755, 659, 559; HPLC: (Chiralcel AS-H, Hexane / *i*-PrOH = 80 : 20, UV = 254 nm, flow rate = 0.7 mL / min) t_{R1} = 39.86 min (major) and t_{R2} = 52.46 min (minor); ee = 99%; [α]_D²⁵ = +11.0 (*c* 0.2, CH₃OH).




(7R,9R)-7-Hydroxy-9-(o-tolyl)-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridine 5,5-dioxide (3p): Pale yellow solid (28.9 mg, 88%). m.p. 72 – 74 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.84 (d, *J* = 7.6 Hz, 1H), 7.72 – 7.64 (m, 2H), 7.60 – 7.56 (m, 1H), 7.24 – 7.18 (m, 4H), 5.93 (d, *J* = 1.6 Hz, 1H), 5.82 (d, *J* = 1.2 Hz, 1H), 4.28 (ddd, *J* = 12.0, 5.6, 2.4 Hz, 1H), 3.74 (s, 1H), 2.47 – 2.44 (m, 1H), 2.43 (s, 3H), 1.87 (t, *J* = 12.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 141.5, 135.7, 133.3, 131.8, 130.6, 130.0, 129.8, 129.1, 127.5, 126.9, 126.7, 121.3, 121.2, 106.0, 72.2, 35.3, 30.9, 19.2; HRMS (ESI): calcd for C₁₈H₁₇NO₃NaS [M+Na]⁺: 350.0827, found 350.0818; IR: 3471, 2928, 2342, 1662, 1489, 1469, 1384, 1305, 1250, 1217, 1200, 1159, 1175, 1062, 1042, 998, 949, 888, 827, 758, 732, 659, 618, 596, 562, 537, 494; HPLC (Chiralcel AS-H, Hexane / *i*-PrOH = 75 : 25, UV = 254 nm, flow rate = 0.35 mL / min) t_{R1} = 36.90 min (major) and t_{R2} = 64.02 min (minor); ee = 94%; [α]_D²⁵ = +16.3 (*c* 0.2, CH₃OH).




(7R,9R)-7-Hydroxy-9-(m-tolyl)-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridine 5,5-dioxide (3q): Colorless oil (27.4 mg, 84%). ¹H NMR (400 MHz, CDCl₃): δ 7.84 (d, *J* = 8.0 Hz, 1H), 7.72 – 7.64 (m, 2H), 7.61 – 7.57 (m, 1H), 7.28 – 7.24 (m, 1H), 7.12 – 7.10 (m, 3H), 5.94 (t, *J* = 2.8 Hz, 1H), 5.85 – 5.82 (m, 1H), 4.02 – 3.97 (m, 1H), 2.49 – 2.43 (m, 1H), 2.37 (s, 3H), 2.00 – 1.93 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 143.6, 138.8, 133.5, 132.2, 130.3, 130.1, 129.1, 129.0, 128.7, 128.0, 125.0, 121.5, 106.0, 72.4, 37.0, 35.1, 21.6; HRMS (ESI): calcd for

C₁₈H₁₇NO₃NaS [M+Na]⁺: 350.0827, found 350.0823; IR: 3457, 2922, 2026, 1640, 1469, 1384, 1306, 1175, 1063, 950, 760; HPLC (Chiralcel AS-H, Hexane / *i*-PrOH = 75 : 25, UV = 254 nm, flow rate = 0.35 mL / min) t_{R1} = 34.60 min (major) and t_{R2} = 57.23 min (minor); ee = 99%; [α]_D²⁵ = +13.7 (*c* 0.2, CH₃OH).




(7*R*,9*R*)-7-Hydroxy-9-(*p*-tolyl)-8,9-dihydro-7*H*-benzo[4,5]isothiazolo[2,3-*a*]pyridine 5,5-dioxide (3r): Colorless oil (28.0 mg, 85%). ¹H NMR (400 MHz, CDCl₃): δ 7.84 – 7.81 (m, 1H), 7.70 – 7.63 (m, 2H), 7.59 – 7.56 (m, 1H), 7.18 (s, 4H), 5.92 (dd, *J* = 5.2, 2.4 Hz, 1H), 5.81 (dd, *J* = 2.8, 1.2 Hz, 1H), 3.99 (ddd, *J* = 12.4, 6.0, 2.4 Hz, 1H), 3.67 (t, *J* = 2.4 Hz, 1H), 2.47 – 2.41 (m, 1H), 2.36 (s, 3H), 1.98 – 1.91 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 140.6, 136.9, 133.5, 132.1, 130.3, 130.0, 129.7, 129.0, 121.5, 121.4, 106.1, 72.4, 37.0, 34.7, 21.2; HRMS (ESI): calcd for C₁₈H₁₇NO₃NaS [M+Na]⁺: 350.0827, found 350.0836; IR: 3457, 2924, 1642, 1513, 1470, 1384, 1305, 1243, 1174, 1159, 1062, 950, 814, 759, 639, 616, 559; HPLC: (Chiralcel AS-H, Hexane / *i*-PrOH = 75 : 25, UV = 254 nm, flow rate = 0.35 mL / min) t_{R1} = 38.88 min (major) and t_{R2} = 58.86 min (minor); ee = 97%; [α]_D²⁵ = +10.8 (*c* 0.4, CH₃OH).




(7*R*,9*R*)-7-Hydroxy-9-(naphthalen-1-yl)-8,9-dihydro-7*H*-benzo[4,5]isothiazolo[2,3-*a*]pyridine 5,5-dioxide (3s): White solid (29.1 mg, 80%). m.p. 104 – 106 °C; ¹H NMR (400 MHz, CDCl₃): δ 8.18 (d, *J* = 8.4 Hz, 1H), 7.92 – 7.90 (m, 1H), 7.86 (d, *J* = 8.0 Hz, 1H), 7.82 – 7.79 (m, 1H), 7.74 (d, *J* = 7.6 Hz, 1H), 7.69 – 7.65 (m, 1H), 7.61 – 7.44 (m, 5H), 6.00 (t, *J* = 2.4 Hz, 2H), 4.86 (s, 1H), 3.74 (s, 1H), 2.69 – 2.63 (m, 1H), 2.08 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 139.5, 134.3, 133.5, 132.2, 131.5, 130.3, 130.1, 129.5, 129.3, 127.9, 126.7, 126.1, 125.9, 125.2, 123.2, 121.5, 121.5, 106.2, 72.6, 35.9, 29.9; HRMS (ESI): calcd for C₂₁H₁₆NO₃S [M-H]⁻: 362.0851, found

362.0843; IR: 3061, 2961, 2925, 2854, 1715, 1668, 1470, 1456, 1338, 1305, 1260, 1176, 1158, 1048, 949, 863, 799, 780, 761, 660, 596, 567; HPLC (Chiralcel AS-H, Hexane / *i*-PrOH = 80 : 20, UV = 254 nm, flow rate = 0.6 mL / min) t_{R1} = 36.72 min (major) and t_{R2} = 57.91 min (minor); ee = 94%; $[\alpha]^{25}_D = -47.3$ (*c* 0.2, CH₃OH).




(7R,9R)-7-Hydroxy-9-(naphthalen-2-yl)-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridine 5,5-dioxide (3t): Pale yellow solid (31.0 mg, 85%). m.p. 122 – 123 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.09 (d, *J* = 8.0 Hz, 1H), 7.98 (d, *J* = 7.6 Hz, 1H), 7.91 – 7.87 (m, 3H), 7.82 (s, 1H), 7.78 – 7.74 (m, 1H), 7.67 (t, *J* = 8.0 Hz, 1H), 7.49 – 7.44 (m, 3H), 6.86 (d, *J* = 6.4 Hz, 1H), 6.14 (t, *J* = 1.2 Hz, 1H), 5.64 – 5.62 (m, 1H), 4.10 – 4.05 (m, 1H), 2.30 – 2.27 (m, 1H), 1.88 – 1.92 (m, 1H); ¹³C NMR (100 MHz, DMSO-*d*₆): δ 142.2, 134.1, 133.9, 132.7, 131.2, 129.8, 129.5, 128.9, 128.2, 128.1, 127.0, 126.8, 126.4, 126.3, 126.0, 122.6, 121.5, 105.3, 71.8, 39.2, 35.0; HRMS (ESI): calcd for C₂₁H₁₆NO₃S [M-H]⁺: 362.0851, found 362.0846; IR: 3502, 3086, 2923, 2850, 1667, 1470, 1454, 1306, 1252, 1175, 1160, 1102, 1035, 995, 950, 760, 729, 701, 603, 556; HPLC (Chiralcel AS-H, Hexane / *i*-PrOH = 80 : 20, UV = 254 nm, flow rate = 0.7 mL / min) t_{R1} = 32.65 min (major) and t_{R2} = 59.76 min (minor); ee = 96%; $[\alpha]^{25}_D = +47.6$ (*c* 0.1, DMSO).




(7R,9R)-9-(Furan-2-yl)-7-hydroxy-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridine 5,5-dioxide (3u): Colorless oil (21.2 mg, 70%). ¹H NMR (400 MHz, CDCl₃): δ 7.83 – 7.80 (m, 1H), 7.72 – 7.69 (m, 1H), 7.67 – 7.63 (m, 1H), 7.59 – 7.55 (m, 1H), 7.38 (dd, *J* = 1.6, 0.8 Hz, 1H), 6.35 (dd, *J* = 2.8, 1.6 Hz, 1H), 6.15 (dt, *J* = 3.2, 0.8 Hz, 1H), 5.95 (d, *J* = 2.0 Hz, 1H), 5.84 (dd, *J* = 2.4, 1.2 Hz, 1H), 4.15 (ddd, *J* = 12.0, 5.6, 2.4 Hz, 1H), 3.60 (t, *J* = 2.0 Hz, 1H), 2.54 – 2.48 (m, 1H), 2.11 – 2.04 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 155.7, 142.0, 133.5, 132.2, 130.4, 129.8,

129.1, 121.5, 121.4, 110.5, 105.3, 102.6, 72.1, 33.2, 28.8; HRMS (ESI): calcd for C₁₅H₁₂NO₄S [M-H]⁻: 302.0487, found 302.0483; IR: 3455, 2924, 2853, 2026, 1638, 14699, 1384, 1305, 1175, 1063, 741, 617; HPLC (Chiralcel AS-H, Hexane / *i*-PrOH = 80 : 20, UV = 254 nm, flow rate = 0.7 mL / min) t_{R1} = 33.47 min (major) and t_{R2} = 47.18 min (minor); ee = 94%; [α]_D²⁵ = +30.9 (*c* 0.2, CH₃OH).



(7R,9R)-7-Hydroxy-9-(thiophen-2-yl)-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridine


5,5-dioxide (3v): White solid (25.5 mg, 80%). m.p. 186 – 187 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.83 (d, *J* = 7.6 Hz, 1H), 7.72 – 7.64 (m, 2H), 7.60 – 7.56 (m, 1H), 7.22 (dd, *J* = 4.8, 1.2 Hz, 1H), 7.00 – 6.97 (m, 2H), 5.93 (t, *J* = 2.8 Hz, 1H), 5.84 (dd, *J* = 2.4, 1.2 Hz, 1H), 4.37 (ddd, *J* = 12.0, 5.6, 2.4 Hz, 1H), 3.67 (s, 1H), 2.59 – 2.53 (m, 1H), 2.09 – 2.02 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 146.8, 133.5, 132.2, 130.5, 129.8, 128.8, 127.2, 124.5, 124.2, 121.6, 121.5, 105.2, 72.2, 37.3, 30.5; HRMS (ESI): calcd for C₁₅H₁₂NO₃S₂ [M-H]⁻: 318.0259, found 318.0253; IR: 2919, 2850, 1731, 1715, 1680, 1661, 1650, 1632, 1470, 1456, 1306, 1259, 1175, 1160, 1101, 1062, 949, 760, 703; HPLC (Chiralcel IC-3, Hexane / *i*-PrOH = 80 : 20, UV = 254 nm, flow rate = 0.9 mL / min) t_{R1} = 41.91 min (major) and t_{R2} = 50.68 min (minor); ee = 89%; [α]_D²⁵ = +40.5 (*c* 0.3, CH₃OH).



(7R,9R)-9-(2-Fluorophenyl)-7-hydroxy-2-methyl-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridine 5,5-dioxide (3w):


White solid (28.3 mg, 82%). m.p. 160 – 162 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.73 (d, *J* = 8.0 Hz, 1H), 7.52 (s, 1H), 7.40 (d, *J* = 8.0 Hz, 1H), 7.32 – 7.27 (m, 2H), 7.18 – 7.08 (m, 2H), 5.95 (dd, *J* = 5.2, 2.8 Hz, 1H), 5.78 (d, *J* = 1.2 Hz, 1H), 4.40 – 4.35 (m, 1H), 3.77 (t, *J* = 2.4 Hz, 1H), 2.53 – 2.47 (m, 4H), 2.03 – 1.95 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 162.3, 159.8, 144.7, 131.7, 131.5, 130.4, 130.3, 129.9, 129.6, 129.4, 129.4, 128.9, 128.8,

124.8, 124.8, 121.6, 121.3, 116.1, 115.9, 104.3, 72.4, 35.0, 28.7, 22.2; HRMS (ESI): calcd for $C_{18}H_{15}NO_3SF$ $[M-H]^-$: 344.0757, found 344.0756; IR: 2922, 2850, 1716, 1489, 1456, 1300, 1262, 1224, 1169, 1145, 1044, 801, 757, 704, 677, 652, 626, 564, 545, 518; HPLC (Chiralcel AS-H, Hexane / *i*-PrOH = 65 : 35, UV = 254 nm, flow rate = 0.35 mL / min) t_{R1} = 36.10 min (major) and t_{R2} = 52.81 min (minor); ee = 99.5%; $[\alpha]^{25}_D$ = +4.3 (*c* 0.1, CH₃OH).




(7R,9R)-2-(tert-butyl)-9-(2-fluorophenyl)-7-hydroxy-8,9-dihydro-7H-

benzo[4,5]isothiazolo[2,3-a]pyridine 5,5-dioxide (3x): White solid (30.9 mg, 80%). m.p. 235 – 236 °C ; ¹H NMR (400 MHz, CDCl₃) δ 7.77 – 7.73 (m, 1H), 7.66 – 7.60 (m, 2H), 7.32 – 7.24 (m, 2H), 7.16 – 7.06 (m, 2H), 5.92 (s, 1H), 5.79 (s, 1H), 4.39 – 4.35 (m, 1H), 3.66 (s, 1H), 2.50 – 2.45 (m, 1H), 1.99 (t, *J* = 12.8 Hz, 1H), 1.36 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 157.8, 130.0, 129.8, 129.4, 129.4, 128.9, 128.8, 128.2, 124.7, 121.1, 117.8, 116.0, 115.8, 104.1, 72.4, 35.7, 34.9, 31.3, 28.6.; HRMS (ESI): calcd for $C_{21}H_{23}NO_3SF$ $[M+H]^+$: 388.1383, found 388.1389; IR: 3501, 2964, 2870, 1669, 1602, 1585, 1560, 1491, 1455, 1431, 1397, 1305, 1265, 1226, 1181, 1153, 1046, 1033, 1005, 964, 824, 759, 628, 661, 595; HPLC (Chiralcel AS-H, Hexane / *i*-PrOH = 93 : 7, UV = 254 nm, flow rate = 0.55 mL / min), t_{R1} = 38.91 min (major) and t_{R2} = 44.58 min (minor); ee = 95%; $[\alpha]^{25}_D$ = – 4.3 (*c* 0.4, CH₃OH).



(7R,9R)-9-(2-fluorophenyl)-7-hydroxy-2-methoxy-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridine 5,5-dioxide (3y): White solid (30.6 mg, 85%). m.p. 184 – 185 °C ; ¹H NMR (400 MHz, CDCl₃) δ 7.72 (dd, *J* = 10.8, 6.4 Hz, 1H), 7.29 – 7.24 (m, 2H), 7.15 – 7.05 (m, 4H), 5.90 (s, 1H), 5.73 (s, 1H), 4.36 (ddd, *J* = 12.0, 5.6, 2.0 Hz, 1H), 3.89 (s, 3H), 2.50 – 2.44 (m, 1H), 1.98 (t, *J* = 13.2 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 164.0, 132.4, 129.5, 129.4, 129.3, 128.9, 128.8, 124.7, 124.7, 123.0, 118.0, 116.0, 115.8, 104.7, 104.5, 72.4, 56.1, 34.8, 28.7; HRMS (ESI): calcd


for $C_{18}H_{17}NO_4SF$ $[M+H]^+$: 362.0862, found 362.0859; IR: 2925, 2855, 1599, 1489, 1477, 1454, 1296, 1260, 1225, 1198, 1170, 1134, 1048, 811, 756; HPLC (Chiralcel AS-H, Hexane / *i*-PrOH = 70 : 30, UV = 254 nm, flow rate = 0.45 mL / min), t_{R1} = 39.46 min (major) and t_{R2} = 56.07 min (minor); ee = 97%; $[\alpha]^{25}_D$ = -2.0 (*c* 0.4, CH₃OH).



(7R,9R)-9-(2-fluorophenyl)-7-hydroxy-2-(trifluoromethyl)-8,9-dihydro-7H-

benzo[4,5]isothiazolo[2,3-a]pyridine 5,5-dioxide (3z): White solid (29.9 mg, 75%). m.p. 172 – 173 °C ; ¹H NMR (400 MHz, CDCl₃) δ 7.99 – 7.95 (m, 2H), 7.82 (d, *J* = 8.0 Hz, 1H), 7.29 – 7.25 (m, 2H), 7.16 – 7.07 (m, 2H), 5.95 (s, 1H), 5.91 (s, 1H), 4.38 (ddd, *J* = 12.0, 5.6, 2.4 Hz, 1H), 3.64 (s, 1H), 2.51 – 2.47 (m, 1H), 2.01 (t, *J* = 12.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 162.2, 134.8, 130.7, 129.6, 129.5, 129.3, 129.3, 129.1, 129.0, 128.5, 127.1, 124.8, 122.5, 118.9, 116.1, 115.9, 106.7, 72.5, 34.7, 28.8; HRMS (ESI): calcd for $C_{18}H_{12}NO_2SF_4$ $[M-OH]^+$: 382.0525, found 382.0524; IR: 3501, 2961, 2926, 2855, 1667, 1585, 1491, 1444, 1261, 1228, 1171, 1135, 1047, 1007, 960, 899, 809, 760, 714, 659, 606, 594; HPLC (Chiralcel AS-H, Hexane / *i*-PrOH = 93 : 7, UV = 254 nm, flow rate = 0.5 mL / min), t_{R1} = 51.17 min (major) and t_{R2} = 74.11 min (minor); ee = 98%; $[\alpha]^{25}_D$ = 22.8 (*c* 0.3, CH₃OH).

5. Procedure for the Synthesis of 4 and 5



(R)-9-(2-Chlorophenyl)-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridine 5,5-dioxide (4):


To a solution of **3f** (34.7 mg, 0.1 mmol) was added triethylsilane (0.2 mmol) in anhydrous DCM (2 mL) and $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (28 μL , 0.22 mol) at -78°C and the reaction mixture was stirred under the same temperature for 2 h. The reaction was quenched with aqueous NaHCO_3 and extracted with DCM. The organic layer was dried over Na_2SO_4 and concentrated. The residue was purified by flash chromatography on silica gel to afford the desired product **4** as a colorless oil (31.5 mg, 95%). ^1H NMR (400 MHz, CDCl_3): δ 7.87 (d, $J = 7.6$ Hz, 1H), 7.72 (d, $J = 7.6$ Hz, 1H), 7.66 (t, $J = 7.2$ Hz, 1H), 7.59 (t, $J = 7.6$ Hz, 1H), 7.45 – 7.39 (m, 1H), 7.29 – 7.19 (m, 3H), 5.67 (d, $J = 4.0$ Hz, 1H), 4.27 (dd, $J = 10.4, 6.0$ Hz, 1H), 3.72 – 3.58 (m, 2H), 2.48 – 2.40 (m, 1H), 2.09 – 2.01 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 141.1, 133.7, 133.2, 132.8, 132.7, 130.3, 130.0, 129.5, 128.5, 127.3, 121.5, 121.2, 102.3, 36.4, 34.8, 28.1; HRMS (ESI): calcd for $\text{C}_{17}\text{H}_{15}\text{NO}_2\text{SCl}$ $[\text{M}+\text{H}]^+$ 332.0512, found 332.0512; IR: 3064, 2927, 2874, 1716, 1732, 1667, 1598, 1569, 1473, 1436, 1377, 1310, 1266, 1254, 1176, 1160, 1063, 1054, 984, 965, 844, 819, 756, 701, 679, 626, 596, 568, 526; HPLC (Chiralcel OD-H, Hexane / *i*-PrOH = 80 : 20, UV = 254 nm, flow rate = 0.8 mL / min) $t_{\text{R}1}$ = 18.91 min (minor) and $t_{\text{R}2}$ = 24.76 min (major); ee = 96%; $[\alpha]_{\text{D}}^{25} = +1.8$ (*c* 0.3, CH_3OH).

(R)-9-(2-Chlorophenyl)-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridin-7-one 5,5-dioxide (5):

A suspension of **3f** (34.7 mg, 0.1 mmol) and IBX (84.0mg, 0.3mmol) in EtOAc (5 mL) was heated under reflux conditions at 100°C . After the reaction mixture was stirred for 12 h, the organic layer was filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel to afford the desired product **5** as a white solid (34.3 mg, 99%). m.p. $212 - 213^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3): δ 7.89 – 7.87 (m, 1H), 7.77 – 7.72 (m, 2H), 7.68 – 7.64 (m, 1H), 7.44 – 7.41 (m, 1H), 7.29 – 7.25 (m, 3H), 6.09 (d, $J = 4.4$ Hz, 1H), 4.63 – 4.58 (m, 1H), 3.16 (dd, $J = 16.4, 7.2$ Hz, 1H), 2.88 (dd, $J = 16.4, 7.6$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 165.5, 138.4, 134.4, 133.4, 132.6, 131.4, 130.7, 130.4, 129.3, 128.2, 128.1, 126.7, 121.9, 121.9, 104.8, 38.1, 35.9; HRMS (ESI): calcd for $\text{C}_{17}\text{H}_{11}\text{NO}_3\text{SCl}$ $[\text{M}-\text{H}]^-$ 344.0148, found 344.0149; IR: 2921, 2850, 1716, 1471, 1346, 1318, 1278, 1182, 1163, 1134, 1051, 1029, 760, 734, 559, 505; HPLC (Chiralcel OD-H, Hexane / *i*-PrOH = 60 : 40, UV = 254 nm, flow rate = 1.0 mL / min) $t_{\text{R}1}$ = 18.24 min (minor) and $t_{\text{R}2}$ = 29.71 min (major); ee = 96%; $[\alpha]_{\text{D}}^{25} = +58.2$ (*c* 0.2, DMSO).

6. X-ray Data of Compound 3f

Structure of Compound 3f



Data of crystal 3f


Table 1. Crystal data and structure refinement of 3f

Identification code	3f
Empirical formula	C ₁₇ H ₁₄ ClNO ₃ S
Formula weight	347.80
Temperature	293 K
Wavelength	0.71073 Å
Crystal system, space group	monoclinic , P 1 21 1
Unit cell dimensions	a = 7.7401(4) Å alpha = 90 deg. b = 14.0157(10) Å beta = 91.699 (5) deg. c = 14.8926(10) gamma = 90 deg.
Volume	1614.88 (18) Å ³
Z, Calculated density	4, 1.431 mg / m ³
F(000)	720.0
wR2 Reflections	0.1783 (5063)
F(000')	721.38
H,k,lmax	9, 16, 17
Nref	5063
Tmin,Tmax	0.894, 1.000


Data completeness	1.64 / 0.85
-------------------	-------------

Note: These data (CCDC 1015580) can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.


7. NMR Spectra




an-tbu-1030
STANDARD 1H OBSERVE




an-tbu-13c-1030
13C OBSERVE







STANDARD 1H OBSERVE




13C OBSERVE







an-cf3-diwu-1027
STANDARD 1H OBSERVE




an-cf3-13c
13C OBSERVE







an-v-73-peak1-badouqu
STANDARD 1H OBSERVE




an-v-73-pak1-13C
13C OBSERVE







an-91-3b-h-072
STANDARD 1H




an-91-3b-13c
13C OBSERVE












an-qingyequan-h
STANDARD 1H OBSERVE







an-185-3-13c
13C OBSERVE








































































an-97-3b-13c-dmso-0726
13C OBSERVE
















an-7-31-3b
STANDARD 1H OBSERVE


7.744 7.728 7.717 7.705 7.279 7.258 7.158 7.140 7.140 7.105 7.088 7.083 7.079 7.075 7.072 5.739 4.382 4.377 4.368 4.363 4.352 4.347 4.338 4.333 4.388 3.706 2.500 2.491 2.478 2.466 2.458 2.445 2.012 1.979 1.949



an-7-31-3b-13c
13C OBSERVE


164.01 132.41 129.58 129.40 129.36 128.92 128.84 124.75 124.72 123.01 118.03 116.07 115.85 104.75 104.58 72.48 56.15 34.87 28.70






an-7-35-3b-cf3
STANDARD 1H OBSERVE





7.993 7.978 7.958 7.835 7.815 7.290 7.274 7.258 7.169 7.150 7.119 7.093 5.915 4.402 4.396 4.388 4.382 4.372 4.366 4.358 4.352 3.643 2.514 2.508 2.495 2.487 2.475 2.047 2.015 1.983




an-7-35-3b-13c-cf3
13C OBSERVE



162.7 134.89 130.71 129.67 129.53 129.36 129.33 129.17 129.08 128.58 127.19 124.82 122.59 118.96 116.17 115.96 106.74 72.52 34.77 28.89










8. HPLC Spectra




Peak	Retention time	Area (%)
1	81.549	49.456
2	110.133	50.544




Peak	Retention time	Area (%)
1	79.517	91.758
2	110.887	8.242




Peak	Retention time	Area (%)
1	45.873	50.306
2	58.032	49.694





Peak	Retention time	Area (%)
1	44.870	95.656
2	58.815	4.344




Peak	Retention time	Area (%)
1	46.175	50.026
2	57.578	49.974





Peak	Retention time	Area (%)
1	44.803	96.762
2	57.902	3.238





Peak	Retention time	Area (%)
1	43.721	49.958
2	54.325	50.042




Peak	Retention time	Area (%)
1	44.427	98.967
2	55.447	1.033








Peak	Retention time	Area (%)
1	32.138	50.372
2	58.344	49.628





Peak	Retention time	Area (%)
1	31.978	99.034
2	59.035	0.966




Peak	Retention time	Area (%)
1	32.138	50.372
2	58.344	49.628





Peak	Retention time	Area (%)
1	31.978	98.993
2	59.035	1.007




Peak	Retention time	Area (%)
1	39.360	50.003
2	63.153	49.997





Peak	Retention time	Area (%)
1	37.065	99.910
2	63.130	0.090




Peak	Retention time	Area (%)
1	57.512	50.107
2	87.641	49.893





Peak	Retention time	Area (%)
1	57.115	99.818
2	89.747	0.182




Peak	Retention time	Area (%)
1	30.621	50.053
2	56.012	49.947





Peak	Retention time	Area (%)
1	30.4000	99.754
2	56.808	0.246




Peak	Retention time	Area (%)
1	32.282	49.644
2	55.903	50.356





Peak	Retention time	Area (%)
1	32.653	99.295
2	61.131	0.705




Peak	Retention time	Area (%)
1	42.154	49.634
2	68.335	50.366





Peak	Retention time	Area (%)
1	40.486	99.356
2	68.166	0.644




Peak	Retention time	Area (%)
1	26.547	50.373
2	41.984	49.627





Peak	Retention time	Area (%)
1	26.622	98.050
2	42.520	1.950




Peak	Retention time	Area (%)
1	45.415	50.284
2	91.343	49.716





Peak	Retention time	Area (%)
1	46.420	100
2	-	0




Peak	Retention time	Area (%)
1	38.749	49.564
2	49.998	50.436





Peak	Retention time	Area (%)
1	39.868	99.399
2	52.461	0.601




Peak	Retention time	Area (%)
1	37.638	49.748
2	64.021	50.252





Peak	Retention time	Area (%)
1	36.900	97.159
2	64.023	2.841




Peak	Retention time	Area (%)
1	34.866	50.002
2	57.053	49.998





Peak	Retention time	Area (%)
1	34.601	99.448
2	57.237	0.552




Peak	Retention time	Area (%)
1	38.975	49.992
2	58.422	50.008





Peak	Retention time	Area (%)
1	38.881	98.677
2	58.867	1.323




Peak	Retention time	Area (%)
1	37.360	49.712
2	57.259	50.288





Peak	Retention time	Area (%)
1	36.725	96.917
2	57.911	3.083




Peak	Retention time	Area (%)
1	32.828	50.258
2	59.003	49.742





Peak	Retention time	Area (%)
1	32.443	98.350
2	59.936	1.650




Peak	Retention time	Area (%)
1	33.687	50.000
2	46.190	50.000





Peak	Retention time	Area (%)
1	33.473	97.399
2	47.182	2.601




Peak	Retention time	Area (%)
1	43.039	49.360
2	51.209	50.640





Peak	Retention time	Area (%)
1	41.918	94.845
2	50.686	5.155




Peak	Retention time	Area (%)
1	37.239	49.797
2	53.095	50.203





Peak	Retention time	Area (%)
1	36.108	99.700
2	52.810	0.300




Peak	Retention time	Area (%)
1	39.023	50.684
2	44.604	49.316





Peak	Retention time	Area (%)
1	38.911	97.729
2	44.583	2.271




Peak	Retention time	Area (%)
1	39.126	49.862
2	55.144	50.138





Peak	Retention time	Area (%)
1	39.466	98.310
2	56.076	1.690




Peak	Retention time	Area (%)
1	51.604	50.905
2	67.565	49.095





Peak	Retention time	Area (%)
1	51.174	98.804
2	74.112	1.196




Peak	Retention time	Area (%)
1	18.885	50.208
2	25.081	49.792



Peak	Retention time	Area (%)
1	18.911	1.731
2	24.766	98.269



Peak	Retention time	Area (%)
1	17.675	49.786
2	29.645	50.214



Peak	Retention time	Area (%)
1	18.241	2.088
2	29.712	97.912